Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.41
+0.15 (0.87%)
At close: Dec 5, 2025, 4:00 PM EST
17.07
-0.34 (-1.95%)
After-hours: Dec 5, 2025, 7:48 PM EST
Monte Rosa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 181.54 | 75.62 | - | - | - | - | |
| Cost of Revenue | 130.57 | 112.86 | 103.37 | - | - | - | |
| Gross Profit | 50.97 | -37.24 | -103.37 | - | - | - | |
| Selling, General & Admin | 42.46 | 43.87 | 39.94 | 35.12 | 15.73 | 4.01 | |
| Research & Development | - | - | - | 77.26 | 57.16 | 24.01 | |
| Operating Expenses | 42.46 | 43.87 | 39.94 | 112.38 | 72.88 | 28.01 | |
| Operating Income | 8.51 | -81.11 | -143.31 | -112.38 | -72.88 | -28.01 | |
| Interest & Investment Income | 11.85 | 10.57 | 9.33 | 3.76 | 0.05 | 0.01 | |
| Currency Exchange Gain (Loss) | 1.54 | 0.42 | -0.93 | 0.01 | -0.16 | -0.2 | |
| Other Non Operating Income (Expenses) | - | - | - | - | -0.96 | -7.68 | |
| EBT Excluding Unusual Items | 21.9 | -70.13 | -134.91 | -108.61 | -73.96 | -35.88 | |
| Gain (Loss) on Sale of Investments | - | - | -0.13 | - | - | - | |
| Gain (Loss) on Sale of Assets | 0.06 | - | 0.02 | 0.11 | - | - | |
| Pretax Income | 21.95 | -70.13 | -135.01 | -108.5 | -73.96 | -35.88 | |
| Income Tax Expense | 1.01 | 2.57 | 0.34 | - | - | - | |
| Net Income | 20.95 | -72.7 | -135.35 | -108.5 | -73.96 | -35.88 | |
| Net Income to Common | 20.95 | -72.7 | -135.35 | -108.5 | -73.96 | -35.88 | |
| Shares Outstanding (Basic) | 82 | 74 | 51 | 47 | 25 | 2 | |
| Shares Outstanding (Diluted) | 83 | 74 | 51 | 47 | 25 | 2 | |
| Shares Change (YoY) | 22.34% | 43.80% | 8.83% | 88.91% | 1548.09% | 7.11% | |
| EPS (Basic) | 0.25 | -0.98 | -2.63 | -2.30 | -2.96 | -23.65 | |
| EPS (Diluted) | 0.25 | -0.98 | -2.63 | -2.30 | -2.96 | -23.65 | |
| Free Cash Flow | 145.02 | 38.01 | -62.84 | -105.38 | -69.1 | -26.44 | |
| Free Cash Flow Per Share | 1.75 | 0.51 | -1.22 | -2.23 | -2.76 | -17.43 | |
| Gross Margin | 28.08% | -49.25% | - | - | - | - | |
| Operating Margin | 4.69% | -107.26% | - | - | - | - | |
| Profit Margin | 11.54% | -96.14% | - | - | - | - | |
| Free Cash Flow Margin | 79.88% | 50.26% | - | - | - | - | |
| EBITDA | 16.84 | -72.99 | -137.09 | -108.64 | -70.75 | -27.47 | |
| EBITDA Margin | 9.28% | -96.52% | - | - | - | - | |
| D&A For EBITDA | 8.33 | 8.12 | 6.22 | 3.75 | 2.13 | 0.54 | |
| EBIT | 8.51 | -81.11 | -143.31 | -112.38 | -72.88 | -28.01 | |
| EBIT Margin | 4.69% | -107.26% | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.